{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:47:18Z","timestamp":1791287238649,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,12,22]],"date-time":"2017-12-22T00:00:00Z","timestamp":1513900800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s00392-017-1193-z","type":"journal-article","created":{"date-parts":[[2017,12,22]],"date-time":"2017-12-22T04:34:28Z","timestamp":1513917268000},"page":"380-388","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":78,"title":["Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins"],"prefix":"10.1007","volume":"107","author":[{"given":"Kathleen M.","family":"Fox","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Hui","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Kostev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Hatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Laufs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,22]]},"reference":[{"issue":"10059","key":"1193_CR1","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","volume":"388","author":"R Collins","year":"2016","unstructured":"Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, Blumenthal R, Danesh J, Smith GD, DeMets D, Evans S, Law M, MacMahon S, Martin S, Neal B, Poulter N, Preiss D, Ridker P, Roberts I, Rodgers A, Sandercock P, Schulz K, Sever P, Simes J, Smeeth L, Wald N, Yusuf S, Peto R (2016) Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 388(10059):2532\u20132561. \n                        https:\/\/doi.org\/10.1016\/S0140-6736(16)31357-5","journal-title":"Lancet"},{"issue":"9493","key":"1193_CR2","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","volume":"366","author":"C Baigent","year":"2005","unstructured":"Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R, Cholesterol Treatment Trialists C (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (9493):1267\u20131278. \n                        https:\/\/doi.org\/10.1016\/S0140-6736(05)67394-1","journal-title":"Lancet"},{"issue":"9753","key":"1193_CR3","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Cholesterol Treatment Trialists","year":"2010","unstructured":"Cholesterol Treatment Trialists C, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376(9753):1670\u20131681. \n                        https:\/\/doi.org\/10.1016\/S0140-6736(10)61350-5","journal-title":"Lancet"},{"issue":"25","key":"1193_CR4","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM, Investigators I-I (2015) Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372(25):2387\u20132397. \n                        https:\/\/doi.org\/10.1056\/NEJMoa1410489","journal-title":"N Engl J Med"},{"issue":"21","key":"1193_CR5","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1001\/archinte.166.21.2307","volume":"166","author":"P Thavendiranathan","year":"2006","unstructured":"Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK (2006) Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Intern Med 166(21):2307\u20132313. \n                        https:\/\/doi.org\/10.1001\/archinte.166.21.2307","journal-title":"Arch Intern Med"},{"key":"1193_CR6","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.atherosclerosis.2016.05.037","volume":"252","author":"MF Piepoli","year":"2016","unstructured":"Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corra U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FD, Lochen ML, Lollgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, Bart van der Worp H, van Dis I, Verschuren WM (2016) 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 252:207\u2013274. \n                        https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.05.037","journal-title":"Atherosclerosis"},{"issue":"14","key":"1193_CR7","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","volume":"32","author":"Z Reiner","year":"2011","unstructured":"European Association for Cardiovascular P, Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D, Guidelines ESCCfP, Committees (2011) ESC\/EAS Guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 32 (14):1769\u20131818. \n                        https:\/\/doi.org\/10.1093\/eurheartj\/ehr158","journal-title":"Eur Heart J"},{"issue":"39","key":"1193_CR8","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","volume":"37","author":"AL Catapano","year":"2016","unstructured":"Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Z, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WM, Vlachopoulos C, Wood DA, Zamorano JL, Authors\/Task Force M, Additional C (2016) 2016 ESC\/EAS guidelines for the management of dyslipidaemias. Eur Heart J 37(39):2999\u20133058. \n                        https:\/\/doi.org\/10.1093\/eurheartj\/ehw272","journal-title":"Eur Heart J"},{"issue":"4","key":"1193_CR9","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bcp.12339","volume":"78","author":"MA Vera De","year":"2014","unstructured":"De Vera MA, Bhole V, Burns LC, Lacaille D (2014) Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review. Br J Clin Pharmacol 78(4):684\u2013698","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"1193_CR10","doi-asserted-by":"publisher","first-page":"357e","DOI":"10.1016\/j.amjmed.2012.09.004","volume":"126","author":"A Bitton","year":"2013","unstructured":"Bitton A, Choudhry NK, Matlin OS, Swanton K, Shrank WH (2013) The impact of medication adherence on coronary artery disease costs and outcomes: a systematic review. Am J Med 126(4):357e\u2013377e. \n                        https:\/\/doi.org\/10.1016\/j.amjmed.2012.09.004","journal-title":"Am J Med"},{"key":"1193_CR11","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2017.0911","author":"LD Colantonio","year":"2017","unstructured":"Colantonio LD, Huang L, Monda KL, Bittner V, Serban MC, Taylor B, Brown TM, Glasser SP, Muntner P, Rosenson RS (2017) Adherence to high-intensity statins following a myocardial infarction hospitalization among medicare beneficiaries. JAMA Cardiol. \n                        https:\/\/doi.org\/10.1001\/jamacardio.2017.0911","journal-title":"JAMA Cardiol"},{"issue":"1","key":"1193_CR12","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.clinthera.2011.12.011","volume":"34","author":"L Degli Esposti","year":"2012","unstructured":"Degli Esposti L, Saragoni S, Batacchi P, Benemei S, Geppetti P, Sturani A, Buda S, Degli Esposti E (2012) Adherence to statin treatment and health outcomes in an Italian cohort of newly treated patients: results from an administrative database analysis. Clin Ther 34(1):190\u2013199. \n                        https:\/\/doi.org\/10.1016\/j.clinthera.2011.12.011","journal-title":"Clin Ther"},{"issue":"Suppl 10","key":"1193_CR13","first-page":"S270","volume":"13","author":"KM Fox","year":"2007","unstructured":"Fox KM, Gandhi SK, Ohsfeldt RL, Davidson MH (2007) Comparison of low-density lipoprotein cholesterol reduction after switching patients on other statins to rosuvastatin or simvastatin in a real-world clinical practice setting. Am J Manag Care 13(Suppl 10):S270\u2013S275","journal-title":"Am J Manag Care"},{"key":"1193_CR14","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.atherosclerosis.2016.09.004","volume":"255","author":"AK Gitt","year":"2016","unstructured":"Gitt AK, Lautsch D, Ferrieres J, Kastelein J, Drexel H, Horack M, Brudi P, Vanneste B, Bramlage P, Chazelle F, Sazonov V, Ambegaonkar B (2016) Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients. Atherosclerosis 255:200\u2013209. \n                        https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.09.004","journal-title":"Atherosclerosis"},{"issue":"5","key":"1193_CR15","doi-asserted-by":"publisher","first-page":"567","DOI":"10.5551\/jat.31179","volume":"23","author":"CE Chiang","year":"2016","unstructured":"Chiang CE, Ferrieres J, Gotcheva NN, Raal FJ, Shehab A, Sung J, Henriksson KM, Hermans MP (2016) Suboptimal control of lipid levels: results from 29 countries participating in the centralized pan-regional Surveys on the undertreatment of hypercholesterolaemia (CEPHEUS). J Atheroscler Thromb 23(5):567\u2013587. \n                        https:\/\/doi.org\/10.5551\/jat.31179","journal-title":"J Atheroscler Thromb"},{"key":"1193_CR16","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.atherosclerosis.2016.01.018","volume":"246","author":"Z Reiner","year":"2016","unstructured":"Reiner Z, De Backer G, Fras Z, Kotseva K, Tokgozoglu L, Wood D, De Bacquer D, Investigators E (2016) Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries\u2013Findings from the EUROASPIRE IV survey. Atherosclerosis 246:243\u2013250. \n                        https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.01.018","journal-title":"Atherosclerosis"},{"issue":"9667","key":"1193_CR17","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/S0140-6736(09)60330-5","volume":"373","author":"K Kotseva","year":"2009","unstructured":"Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Keil U, Group ES (2009) Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 373(9667):929\u2013940. \n                        https:\/\/doi.org\/10.1016\/S0140-6736(09)60330-5","journal-title":"Lancet"},{"issue":"6","key":"1193_CR18","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1177\/2047487315569401","volume":"23","author":"K Kotseva","year":"2016","unstructured":"Kotseva K, Wood D, De Bacquer D, De Backer G, Ryden L, Jennings C, Gyberg V, Amouyel P, Bruthans J, Castro Conde A, Cifkova R, Deckers JW, De Sutter J, Dilic M, Dolzhenko M, Erglis A, Fras Z, Gaita D, Gotcheva N, Goudevenos J, Heuschmann P, Laucevicius A, Lehto S, Lovic D, Milicic D, Moore D, Nicolaides E, Oganov R, Pajak A, Pogosova N, Reiner Z, Stagmo M, Stork S, Tokgozoglu L, Vulic D, Investigators E (2016) EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol 23(6):636\u2013648. \n                        https:\/\/doi.org\/10.1177\/2047487315569401","journal-title":"Eur J Prev Cardiol"},{"issue":"4","key":"1193_CR19","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.amjcard.2015.11.035","volume":"117","author":"RG Quek","year":"2016","unstructured":"Quek RG, Fox KM, Wang L, Li L, Gandra SR, Wong ND (2016) A US claims-based analysis of real-world lipid-lowering treatment patterns in patients with high cardiovascular disease risk or a previous coronary event. Am J Cardiol 117(4):495\u2013500. \n                        https:\/\/doi.org\/10.1016\/j.amjcard.2015.11.035","journal-title":"Am J Cardiol"},{"issue":"11","key":"1193_CR20","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","volume":"47","author":"M Charlson","year":"1994","unstructured":"Charlson M, Szatrowski TP, Peterson J, Gold J (1994) Validation of a combined comorbidity index. J Clin Epidemiol 47(11):1245\u20131251","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"1193_CR21","doi-asserted-by":"publisher","first-page":"e001800","DOI":"10.1161\/JAHA.112.001800","volume":"1","author":"PH Jones","year":"2012","unstructured":"Jones PH, Nair R, Thakker KM (2012) Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis. J Am Heart Assoc 1(6):e001800. \n                        https:\/\/doi.org\/10.1161\/JAHA.112.001800","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"1193_CR22","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.atherosclerosis.2013.02.027","volume":"228","author":"BW Karlson","year":"2013","unstructured":"Karlson BW, Nicholls SJ, Lundman P, Palmer MK, Barter PJ (2013) Achievement of 2011 European low-density lipoprotein cholesterol (LDL-C) goals of either < 70 mg\/dl or \u2265 50% reduction in high-risk patients: results from VOYAGER. Atherosclerosis 228 (1):265\u2013269. \n                        https:\/\/doi.org\/10.1016\/j.atherosclerosis.2013.02.027","journal-title":"Atherosclerosis"},{"issue":"9","key":"1193_CR23","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s00392-016-0991-z","volume":"105","author":"U Laufs","year":"2016","unstructured":"Laufs U, Karmann B, Pittrow D (2016) Atorvastatin treatment and LDL cholesterol target attainment in patients at very high cardiovascular risk. Clin Res Cardiol 105(9):783\u2013790. \n                        https:\/\/doi.org\/10.1007\/s00392-016-0991-z","journal-title":"Clin Res Cardiol"},{"issue":"1","key":"1193_CR24","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1136\/jim-2016-000218","volume":"65","author":"IA Mansi","year":"2017","unstructured":"Mansi IA, Frei CR, Halm EA, Mortensen EM (2017) Association of statins with diabetes mellitus and diabetic complications: role of confounders during follow-up. J Investig Med 65(1):32\u201342. \n                        https:\/\/doi.org\/10.1136\/jim-2016-000218","journal-title":"J Investig Med"},{"issue":"24","key":"1193_CR25","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1001\/jama.2011.860","volume":"305","author":"D Preiss","year":"2011","unstructured":"Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P, Cannon CP, Sabatine MS, Braunwald E, Kastelein JJ, de Lemos JA, Blazing MA, Pedersen TR, Tikkanen MJ, Sattar N, Ray KK (2011) Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 305(24):2556\u20132564. \n                        https:\/\/doi.org\/10.1001\/jama.2011.860","journal-title":"JAMA"},{"key":"1193_CR26","doi-asserted-by":"publisher","unstructured":"Spence JD, Dresser GK (2016) Overcoming Challenges With Statin Therapy. J Am Heart Assoc 5 (1). \n                        https:\/\/doi.org\/10.1161\/JAHA.115.002497","DOI":"10.1161\/JAHA.115.002497"},{"issue":"11","key":"1193_CR27","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s00392-010-0177-z","volume":"99","author":"AK Gitt","year":"2010","unstructured":"Gitt AK, Junger C, Smolka W, Bestehorn K (2010) Prevalence and overlap of different lipid abnormalities in statin-treated patients at high cardiovascular risk in clinical practice in Germany. Clin Res Cardiol 99(11):723\u2013733. \n                        https:\/\/doi.org\/10.1007\/s00392-010-0177-z","journal-title":"Clin Res Cardiol"},{"key":"1193_CR28","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.dib.2016.09.037","volume":"9","author":"AK Gitt","year":"2016","unstructured":"Gitt AK, Lautsch D, Ferrieres J, Kastelein J, Drexel H, Horack M, Brudi P, Vanneste B, Bramlage P, Chazelle F, Sazonov V, Ambegaonkar B (2016) Contemporary data on low-density lipoprotein cholesterol target value attainment and distance to target in a cohort of 57,885 statin-treated patients by country and region across the world. Data Brief 9:616\u2013620. \n                        https:\/\/doi.org\/10.1016\/j.dib.2016.09.037","journal-title":"Data Brief"},{"issue":"3","key":"1193_CR29","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1185\/03007995.2015.1120715","volume":"32","author":"AK Gitt","year":"2016","unstructured":"Gitt AK, Sonntag F, Jannowitz C, Weizel A, Karmann B, Schaefer JR, Pittrow D, Hildemann SK (2016) Better lipid target achievement for secondary prevention through disease management programs for diabetes mellitus and coronary heart disease in clinical practice in Germany. Curr Med Res Opin 32(3):417\u2013426. \n                        https:\/\/doi.org\/10.1185\/03007995.2015.1120715","journal-title":"Curr Med Res Opin"},{"issue":"11","key":"1193_CR30","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1080\/14779072.2016.1221341","volume":"14","author":"M Drakopoulou","year":"2016","unstructured":"Drakopoulou M, Toutouzas K, Stathogiannis K, Synetos A, Trantalis G, Tousoulis D (2016) Managing the lipid profile of coronary heart disease patients. Expert Rev Cardiovasc Ther 14(11):1263\u20131271. \n                        https:\/\/doi.org\/10.1080\/14779072.2016.1221341","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"1193_CR31","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw572","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS (2017) Proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors: comparing and contrasting guidance across the Atlantic. Eur Heart J. \n                        https:\/\/doi.org\/10.1093\/eurheartj\/ehw572","journal-title":"Eur Heart J"},{"key":"1193_CR32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615664","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR, Committee FS, Investigators (2017) Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. \n                        https:\/\/doi.org\/10.1056\/NEJMoa1615664","journal-title":"N Engl J Med"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00392-017-1193-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-017-1193-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-017-1193-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,4,23]],"date-time":"2018-04-23T07:55:22Z","timestamp":1524470122000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00392-017-1193-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,22]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["1193"],"URL":"https:\/\/doi.org\/10.1007\/s00392-017-1193-z","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,22]]}}}